YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
May 14, 16:00
5195.85
-106.15 (-2%)
VOLUME 233,088
LIVE
NSE
May 14, 15:59
5196.85
-104.6 (-1.97%)
VOLUME 2,977,011
News on Dr Reddys Laboratories
Select Year: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Dr Reddy's seeks approval from Health Canada for Favipiravir

12.49 pm | 22 Dec 2020 |  Source: PTI

The application was filed under Health Canada's "Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to CO...

This is how DBT is helping companies accelerate development of COVID-19 vaccine

7.08 pm | 07 Dec 2020 |  Source: Moneycontrol.com

The Department of Biotechnology has prepared 11 clinical trial sites across the country that would help developers test the COVID-19 vaccine candidate...

Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine

7.48 am | 29 Nov 2020 |  Source: PTI

The acquired brands represent two types of products -- mometasone mono product and combination of mometasone with azelastine, which are indicated for ...

Russia's Sputnik V COVID-19 vaccine to be produced in India; RDIF and Hetero agree to make over 100 million doses

1.00 pm | 27 Nov 2020 |  Source: Moneycontrol.com

COVID-19 Vaccine Tracker: This is the second such partnership by an Indian company with RDIF. Earlier, Dr Reddy's partnered with RDIF to conduct c...

COVID vaccine | Sputnik V shows 91.4% efficacy in second interim analysis on day 28 after first dose

5.04 pm | 24 Nov 2020 |  Source: Moneycontrol.com

The cost of one dose of the Sputnik V vaccine for international markets will be less than $10. Sputnik V is a two dose vaccine....

Why Lupin’s Solosec is a cautionary tale for the much-hyped speciality drug business

4.58 pm | 10 Nov 2020 |  Source: Moneycontrol.com

The company’s speciality business has contracted 50 percent, as Covid continues to take a toll and limits its ability to promote Solosec to prescrib...

Buy Dr. Reddy's; target of Rs 6050: Emkay Global Financial

12.13 pm | 05 Nov 2020 |  Source: Moneycontrol.com

Emkay Global Financial is bullish on Dr. Reddy's has recommended buy rating on the stock with a target price of Rs 6050 in its research report dat...

Buy Dr Reddy's Laboratories; target of Rs 6000: ICICI Direct

9.37 pm | 04 Nov 2020 |  Source: Moneycontrol.com

ICICI Direct is bullish on Dr Reddy's Laboratories recommended buy rating on the stock with a target price of Rs 6000 in its research report dated...

Accumulate Dr. Reddy’s laboratories; target of Rs 5418 KR Choksey

8.53 pm | 04 Nov 2020 |  Source: Moneycontrol.com

KR Choksey recommended accumulate rating on Dr. Reddy’s laboratories with a target price of Rs 5418 in its research report dated October 30, 2020....

Accumulate Dr Reddy's Laboratories; target of Rs 5414: Dolat Capital Market

4.58 pm | 03 Nov 2020 |  Source: Moneycontrol.com

Dolat Capital Market recommended accumulate rating on Dr Reddy's Laboratories with a target price of Rs 5414 in its research report dated October ...

Buy Dr. Reddy's Laboratories; target of Rs 5964: Prabhudas Lilladher

4.36 pm | 03 Nov 2020 |  Source: Moneycontrol.com

Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5964 in its research ...

Dr Reddy’s: Better US prospects to sustain valuations

3.52 pm | 29 Oct 2020 |  Source: Moneycontrol.com

Dr Reddy's US growth prospects have improved after its recent settlement with Bristol Myers Squibb to launch an oncology drug...

Dr Reddys Labs Consolidated September 2020 Net Sales at Rs 4,910.90 crore, up 2.04% Y-o-Y

10.22 am | 29 Oct 2020 |  Source: Moneycontrol.com

NULL...

Dr Reddys Labs Standalone September 2020 Net Sales at Rs 3,345.80 crore, down 2.91% Y-o-Y

9.44 am | 29 Oct 2020 |  Source: Moneycontrol.com

NULL...

Dr Reddy's plans to complete phase 3 trial of Sputnik V COVID vaccine by March end

9.19 pm | 28 Oct 2020 |  Source: Moneycontrol.com

CEO Erez Israeli said the company would begin phase II trials in the next few days...

Cyber attack that led to pause in worldwide operations was ransomware, investigation continues: Dr Reddy's

3.44 pm | 28 Oct 2020 |  Source: Moneycontrol.com

In a ransomware attack, the hackers breach the systems, install malware that encrypts a victim's files, then demand a ransom from the victim to re...

Dr Reddy's Labs Q2 profit falls 30% to Rs 762 crore, global generics business up 21%

1.54 pm | 28 Oct 2020 |  Source: Moneycontrol.com

The YoY revenue growth stood at 20 percent after adjusted for proprietary products out-licensing income in the previous year, the company said in its ...

Dr Reddy's launches generic product in US to treat gastroesophageal reflux disease

4.18 pm | 20 Oct 2020 |  Source: PTI

Famotidine tablets are used to prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certai...

Russia's COVID-19 vaccine Sputnik V makes headway in India

12.23 pm | 18 Oct 2020 |  Source: Moneycontrol.com

Dr Reddy's gets the nod to conduct human trials for the vaccine while Mankind Pharma signs an agreement with RIDF that will make 300 million doses...

Accumulate Dr. Reddy's Laboratories; target of Rs 5648: Prabhudas Lilladher

12.57 pm | 06 Oct 2020 |  Source: Moneycontrol.com

Prabhudas Lilladher recommended accumulate rating on Dr. Reddy's Laboratories with a target price of Rs 5648 in its research report dated October ...

1 2 3 4
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.